Diabetes mellitus affects more than 10% of people with HIV, and its incidence is rising as the population ages, according to the National Institutes of Health. Antiretroviral therapies that treat HIV by blocking specific enzymes the virus uses to multiply can cause metabolic complications, including weight gain and insulin resistance. Since 2015, integrase strand transfer inhibitor-based regimens have been recommended as first-line treatment. In a new Johns Hopkins Medicine study, researchers found adults with HIV who switched from protease inhibitors to integrase inhibitors were at increased risk of diabetes.
This article was originally published on MedicalXpress.com
